In the last two decades, the discovery of various pathways involved in renal cell carcinoma (RCC) have led to the development of biologically-driven targeted therapies. Hypoxia inducible factors (HIFs), angiogenic growth factors, von Hippel-Lindau (VHL) gene mutations and oncogenic miRNAs play essential roles in the pathogenesis and drug resistance of clear cell renal cell carcinoma. These insights have led to the development of VEGF inhibitors, mTOR inhibitors and immunotherapeutic agents which have significantly improved outcomes of patients with advanced RCC. HIF inhibitors will be a valuable asset in the growing therapeutic armamentarium of RCC. Various histone deacetylase (HDAC)inhibitors, including selenium and agents such as PT2385 and PT2977, are being explored in various clinical trials as potential HIF inhibitors to ameliorate the outcomes of RCC patients. In this article, we will review the current treatment options and highlight the potential role of selenium in the modulation of drug resistance biomarkers expressed in ccRCC tumors.
Introduction
Clear cell renal cell carcinoma (ccRCC) is the most common malignancy in the kidney.
Over 65,000 new kidney cancer cases and 14,000 deaths were estimated in the United States in 2018 (1) . RCC is the most lethal genitourinary cancer given its disease course is largely asymptomatic and incidentally found in more than half of new cases (2, 3) . Established modifiable risk factors for RCC include obesity, smoking, and hypertension (4) . Other studies link alcohol use, type 2 diabetes, and occupational or environmental exposures to increased risk of RCC (5) .
RCC is categorized into three major histological subtypes: ccRCC, comprising 70% of cases, papillary and chromophobe RCC, which together comprise 25% of cases, and tumors of the medullary and collecting systems, which comprise 5% of cases (6, 7) . These subtypes arise from distinct genetics and therefore are treated differently (8) .
Localized RCC is often managed surgically with partial or radical nephrectomy, with tumor ablation or active surveillance for small tumors. Systemic therapy is primarily reserved for metastatic RCC. Current evidence for adjuvant systemic therapy after complete resection of the tumor has shown no survival benefit (9) . For stage IV disease, cytoreductive nephrectomy in addition to systemic therapy has not shown improvement in overall survival (9, 10) . In the last two decades, there has been significant improvement in our knowledge of renal cell carcinogenesis that has, in turn, led to the development of biologically-driven targeted therapies.
Role of HIF in Renal Cell Carcinogenesis
Adaptation to a hypoxic environment is a key attribute of cancer cells. This is mediated via transcription factors called hypoxia inducible factors (HIF). These factors are heterodimers 4 with an α-subunit (HIF1α, HIF2α or HIF3α) and a β-subunit (HIF1β) (11) . Previously, HIF1α was considered to be a predominant oncogenic driver but recent evidence shows HIF2 α as a key player in renal cancer progression (12) . In addition to hypoxia, there are additional oncogenic signaling pathways (e.g., PI3K, RAS) that are known to regulate HIF activation. Once activated, HIF transcription factors translocate in the nucleus and bind to the hypoxia response elements which leads to transcription of several target genes involved in angiogenesis (VEGF), oxygen transport and metabolism (erythropoietin), glycolysis (LDH), glucose transport (GLUT1), cell proliferation and migration, which eventually leads to carcinogenesis (Figure 1 ) (13, 14) . VEGF plays a vital role in the tumor angiogenesis and is a key target of anti-cancer therapeutic agents.
Regulation of HIF-1 pathway is vital for cellular homeostasis.
Regulation of HIF Pathway by VHL Gene
Von Hippel-Lindau (VHL) is a tumor suppressor gene located on the short arm of chromosome 3 that is commonly mutated in both hereditary and sporadic renal cell carcinoma.
The VHL gene encodes two isoforms of VHL proteins (pVHL) that play a crucial role in cellular oxygen sensing. In normoxic conditions, the pVHL ubiquitin ligase complex binds to the hydroxylated HIF1α and HIF2α, which subsequently undergoes ubiquitination and proteasomal degradation. However, in cellular hypoxic conditions, pVHL cannot bind to HIF1α and HIF2α, as these transcriptional factors are not hydroxylated by prolyl hydroxylases, which is an oxygendependent process, leading to their accumulation and activation of downstream pathways (15, 16) . A wide range of intragenic mutations, deletions (complete or partial) and splicing defects have been identified that derange normal function of the VHL gene (17) . This interdependency on biological pathways by cancer cells has laid the foundation for development of several targeted therapeutic agents for the treatment of advanced renal cell carcinoma.
Angiogenesis (VEGF Pathway) Inhibitors
Current first-line therapy for stage IV, unresectable, or relapsed disease of clear cell histology includes the oral VEGF tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib (9) .
Additionally, for intermediate to poor risk groups based on the international metastatic renal cell carcinoma database consortium (IMDC) criteria (19) , either the combination of ipilimumab and nivolumab or cabozantinib are options.
Sunitinib is a multi-kinase inhibitor targeting several tyrosine kinase receptors, including platelet-derived growth factor receptors (PDGFR-α and β), VEGF receptors (VEGFR-1, -2, and -3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase (FLT-3), colony-stimulating factor (SSF-1R), and neurotropic factor receptor (RET) (9) . In the landmark phase 3, multicenter clinical trial by Motzer et al., sunitinib was compared with interferon-α in patients with previously untreated metastatic renal-cell carcinoma (20) . Progression-free survival (PFS) in the 6 sunitinib arm was 11 months and in the interferon-α arm the PFS was 5 months. The overall survival (OS) with sunitinib was 26 months.
Pazopanib is another oral angiogenesis inhibitor targeting VEGFR-1, -2 and -3, PDGFR-α and -β, and c-KIT. In a phase III, open-label study of pazopanib in patients with no prior treatment or one prior cytokine-based treatment, PFS was prolonged significantly with pazopanib versus placebo. For the treatment naïve group, PFS was 11.1 months compared to 2.8 months for pazopanib and placebo, respectively (21) . In a phase 3 non-inferiority trial, pazopanib was compared to sunitinib in patients with advanced renal cell carcinoma. The study was positive for non-inferiority with a progression-free survival of 8.4 and 9.5 months for pazopanib and sunitinib, respectively (22) . In addition, the median OS with pazopanib was 28.3 months and 29.1 months for sunitinib. In subgroup analysis for patients with favorable-risk disease, the median OS for pazopanib and sunitinib was found to be 52.5 and 43.6 months, respectively (23) .
Both of these medications had similar rates of adverse events that led to dose reduction and had no differences in grades 3/4 adverse events. Symptoms associated with discomfort such as fatigue, hand-foot syndrome and mouth sores occurred more frequently with sunitinib while pazopanib was associated with elevations in liver-function tests, weight loss, and changes in hair color. The study also showed lower monthly use of medical resources with pazopanib than with sunitinib (22) .
Cabozantinib is a small molecule inhibitor of tyrosine kinases, which include VEGF receptors, MET and AXL (9) . Cabozantinib was compared to sunitinib in a phase 2 study of intermediate to poor IMDC risk, treatment naïve patients with metastatic RCC (24) . In this study, PFS was 8.6 months versus 5.3 months for cabozantinib and sunitinib, respectively, and median OS was found to be 34.5 months and 26.6 months, respectively. Based on these results, 7 cabozantinib has been approved by the FDA as a first-line agent. Cabozantinib has also been studied in a phase III trial (METEOR trial) of patients with disease progression after previous TKI therapy (25) . The study compared second-line therapy with cabozantinib versus everolimus.
The results showed median PFS of 7.4 months as compared to 3.8 months for cabozantinib and everolimus, respectively. Thus, in addition to first-line therapy, cabozantinib is a viable option as a second-line therapy for patients with disease progression on other TKI therapy.
Axitinib is a selective, second-generation tyrosine kinase inhibitor targeting VEGFR-1, -2, and -3 (9). The phase III AXIS trial compared axitinib and sorafenib as second-line therapy following other systemic therapy. PFS was 6.7 for axitinib versus 4.7 months for sorafenib. PFS was favored in both subgroups of patients treated with axitinib whose prior systemic therapy was sunitinib or cytokine therapy. Median OS was 20.1 months with axitinib as compared to 19.2 months with sorafenib, although, this was not statistically significant (26) .
Bevacizumab along with interferon (IFN) alfa-2b also has category 1 level of evidence for first-line therapy. It is a recombinant humanized monoclonal antibody that binds to circulating VEGF-A. A double-blind phase III trial (AVOREN) compared bevacizumab plus IFN-alfa-2b versus placebo plus IFN-alfa-2b (27) . With the addition of bevacizumab, PFS was significantly increased (10.4 vs. 5.4 months) with a tumor response rate of 30.6% in the bevacizumab group compared to 12.4% in the placebo group. This was achieved without significant increase in adverse events. OS was improved in the bevacizumab group versus the placebo group (23.3 months vs. 21.3 months); however, this was not statistically significant. HIF regulation, either by blocking its production, antagonizing it effects or by enhancing its degradation, has provided multiple opportunities to expand the current therapeutic armamentarium of renal cell carcinoma. In a small study of mRCC, HIF expression was predictive of increased response to sunitinib treatment (36) . In this study, 26 of 49 patients had high HIF1α and HIF2α expression on the tumor cells (based on immunoblot analysis). These patients had a higher rate of complete response or partial response when compared to patients with low or absent HIF1α/HIF2α expression. In either case, these results will require further mechanistic studies before they can be explained.
Mechanistic Target of Rapamycin (mTOR) Inhibitors
There is evidence to suggest complex interactions among these loci. 
Role of Selenium in HIF Pathway
Selenium is an essential micronutrient; in the human body it is involved with the regulation of cell metabolism, DNA and RNA as well as protein synthesis, and is at the active site of several enzymes of the antioxidant network. Inorganic forms of selenium, such as selenide and selenite, are converted by plants into organic forms, such as selenomethione (SLM) and Semethylselenocysteine (MSC), that are retained in the human body. Studies have shown that 12 serum levels of selenium vary from person to person. Dietary intake is influenced by the soil levels of selenium of plants we ingest. Epidemiologic studies have suggested that dietary selenium intake is a protective factor in developing some forms of cancer such as colorectal, prostate, lung, and bladder cancer (37) (38) (39) (40) .
SLM and MSC are forms of selenium that are currently being investigated as possible anti-tumor agents. In their natural form, these agents have a relatively low toxicity profile. They are converted via β-lyase to the active form methylselenol (MSA). HIF1α appears to be a target of selenium. In pre-clinical studies of head and neck squamous cell carcinoma cells that express HIF1α, it was found that in the setting of hypoxia where HIF1α expression is increased, the cytotoxicity of SN38, the active metabolite of irinotecan, was enhanced with the addition of MSA (41) . This is possibly due to the inhibition of HIF1α by MSA and demonstrates the potential for reversal of chemoresistance by MSA. Moreover, selenium has been found to target β-catenin, and increases drug cytotoxicity through the reduction of β-catenin's drug resistant effects (42) . Selenium compounds may also improve efficaciousness of other anti-tumor agents through reduction in treatment-induced toxicities, allowing for higher tolerated doses. In one study of A253 and HT 29 xenografts, coadministration of MSC with irinotecan at two to three times the maximum tolerated dose of irinotecan led to response without intolerable toxicity (43) .
Selenium can also affect the tumor microenvironment (TME) and may be able to stabilize the TME to improve drug delivery. MSC has an anti-vascular effect and can increase the antitumor effect of irinotecan through the inhibition of HIF1α which leads to decreased microvessel density, lowered tumor interstitial pressure, and increased pericyte coverage of blood vessels (41). 14 selenium interacts with other chemotherapies, the tumor microenvironment, its interaction with miRNA and transcription factors make it a very favorable target for further research.
Studies on HIF Inhibitors in Advanced Renal Cell Carcinoma
PT2385 is a HIF-2α antagonist that was evaluated in a phase 1, standard 3+3 dose escalation study of heavily pretreated metastatic ccRCC (47) . In this study, 51 patients were treated with oral PT2385 twice a day and the recommended phase-2 dose (RP2D) was 800 mg BID. One patient had complete response (2%) and 6 had partial response (12%) and the rest had either stable disease or progression. No dose-limiting toxicities were noted. The most common treatment-related side effects included anemia, peripheral edema, fatigue and nausea.
Considering the promising response signals of a single agent in a heavily pretreated patient population, further studies are ongoing with combination PT2385 with nivolumab and cabozantinib, respectively (NCT02293980).
In a multi-institutional, phase I/II clinical trial, vorinostat (histone deacetylase inhibitor) was evaluated in combination with bevacizumab in ccRCC patients (48) . HDAC inhibitors modulate the HIF pathway by affecting Hsp90 acetylation and HIF-α nuclear translocation (49, 50) . In this study, 33 evaluable patients were treated with vorinostat 200 mg orally twice daily for 2 weeks in combination with bevacizumab 15 mg/kg administered intravenously every 3 weeks. There were no dose-limiting toxicities. Two patients had grade 4 thrombocytopenia. The most common adverse events included fatigue, nausea, pain, anorexia, diarrhea and elevated creatinine. About 10 patients discontinued therapy due to toxicities, but there were no treatmentrelated deaths. One patient achieved complete response and 5 patients had partial response. 15 Currently a phase I/Ib study of pembrolizumab with vorinostat is in progress for patients with advanced renal or urothelial cell carcinoma (NCT02619253).
The safety and efficacy of another HDAC inhibitor, abexinostat, as an epigenetic downregulator of HIF-1α and VEGF expression, was evaluated in combination with pazopanib by Aggarwal and colleagues in a study of advanced solid tumor malignancies (51) . The RCC cohort included 22 patients. The dosing schedule of adexinostat was modified due to 5 doselimiting toxicities that included grade 3 thrombocytopenia (n = 2), grade 3 fatigue (n = 2) and grade 3 AST/ALT elevation (n = 1). There were no treatment-related deaths. The objective response rate in the RCC cohort was 27% including patients who were previously refractory to 
